R R

What is Carcinoid Syndrome?

Carcinoid Syndrome is a collection of severe symptoms caused by the release of excessive amounts of hormones (such as serotonin) into the bloodstream by carcinoid tumors, which are a rare type of cancer.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What is Carcinoid Syndrome?

Carcinoid Syndrome is a collection of severe symptoms caused by the release of excessive amounts of hormones (such as serotonin) into the bloodstream by carcinoid tumors, which are a rare type of cancer.

read more about carcinoid syndrome ...

Copy this HTML:

Copy HTML Copied!

Where Do Carcinoid Tumours Typically Originate and Spread?

Carcinoid tumors typically originate in the gastrointestinal tract (stomach, small intestine, appendix, or colon) or in the lungs. The severe symptoms of the syndrome usually appear only after the tumors have metastasized (spread) to the liver.

This spread is the central mechanism, as it allows the released hormones to bypass the liver's filtering system and enter the general circulation, causing widespread effects. Early detection of the primary tumor is often difficult due to minimal early symptoms, so the first noticeable signs often appear once the liver is involved.

What Are the Characteristic Systemic Symptoms and Triggers?

The characteristic systemic symptoms include severe flushing (sudden, intense redness of the face and neck), persistent diarrhea, and wheezing or shortness of breath. The intensity of the flushing can be debilitating and may be triggered by stress, alcohol, or large meals, making ongoing monitoring necessary.

These symptoms reflect high levels of hormones such as serotonin acting on various organs, including the skin and bowels. The diarrhea is often explosive and can be severe, leading to dehydration and malnutrition.

What is the Connection to Hormone Release?

The connection lies in the uncontrolled release of hormones like serotonin. Since the liver usually filters these hormones, their entry into the general bloodstream in high amounts causes the widespread symptoms associated with the syndrome. The specific set of symptoms depends on the type of hormone secreted by the tumor, though serotonin is the most common mediator of the flushing.

How Does This Condition Impact Vision or Eye Health?

Carcinoid Syndrome directly impacts eye health by causing severe and sustained conjunctival injection (redness or dilation of blood vessels in the whites of the eyes). Severe, frequent flushing episodes can cause the blood vessels on the eye's surface to become prominent and permanently visible, a form of telangiectasia.

How are Carcinoid Tumours and Syndrome Managed?

Management involves a combination of strategies. Tumors are treated with surgery, chemotherapy, or targeted therapies. The severe hormonal symptoms of the syndrome are managed with medications like somatostatin analogs, which help block the release of the excess hormones.

FAQs on Carcinoid Syndrome

Are carcinoid tumours always malignant?

Yes, carcinoid tumors are cancerous, but they are often slow-growing compared to many other types of cancer.

Is flushing the only symptom?

No, while flushing is characteristic, persistent diarrhea and wheezing are also major symptoms that define the syndrome.

Does everyone get the syndrome?

No, the syndrome only occurs when the tumors have spread, typically to the liver, allowing the hormones to bypass the body's filtering system.

When to See Your Doctor

Consult a doctor for unexplained facial flushing or chronic diarrhea. Carcinoid Syndrome can cause "Pellagra-like" skin changes and rarely, deposits on the surface of the eye. Diagnosis often involves a 24-hour urine test for 5-HIAA.

References

American Cancer Society. Carcinoid Tumors (cancer.org). 2024.

Mayo Clinic. Carcinoid Syndrome (mayoclinic.org). 2024.

Cleveland Clinic. Carcinoid Syndrome (clevelandclinic.org). 2024.

StatPearls. Carcinoid Syndrome (ncbi.nlm.nih.gov). 2024.